Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

HuGENet Review

HFE Gene and Hereditary Hemochromatosis
E. H. Hanson1, G. Imperatore2, W. Burke3

back to review

 REFERENCES
  1. Simon M, Bourel M, Fauchet R, et al. HLA and "non-immunological" disease: idiopathic haemochromatosis [letter]. Lancet 1976;2:973-4.
  2. Cartwright GE, Skolnick M, Amos DB, et al. Inheritance of hemochromatosis: linkage to HLA. Trans Assoc Am Physicians 1978;91:273-81.
  3. Dadone MM, Kushner JP, Edwards CQ, et al. Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees. Am J Clin Pathol 1982;78:196-207.
  4. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.>
  5. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Vox Sang 1997;73:105-30.
  6. Rhodes DA, Trowsdale J. Alternate splice variants of the hemochromatosis gene HFE. Immunogenetics 1999;49:357-9.
  7. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998;95:1472-7.
  8. Lebron JA, Bennet MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998;93:111-23.
  9. Waheed A, Parkkila S, Saarnio J, et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci U S A 1999;96:1579-84.
  10. Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2- microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8.
  11. Parkilla S, Waheed A, Britton RS, et al. Immunohistochemistry of HLA-H, the protein defective in patients with hemochromatosis, reveals unique pattern of expression in hereditary hemochromatosis. Proc Natl Acad Sci USA 1997;94:2534-39.
  12. Zhou XY, Tomatsu S, Fleming RE, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 1998;95:2492-7.
  13. Pointon JJ, Wallace D, Merryweather-Clarke AT, et al. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genetic Testing 2000;4:151-61.
  14. Mura C, Raguenes O. HFE mutations analysis in 711 hemochromatosis probands: Evidence for S65C implication in mild form of hemochromatosis. Blood 1999;93:2502-5.
  15. Jeffrey GP, Chakrabarti S, Hegele RA, et al. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet 1999;22:325-6.
  16. Sommerville MJ, Sprysak KA, Hicks M, et al. An HFE intronic variant promotes misdiagnosis of hereditary hemochromatosis [letter]. Am J Hum Genet 1999;65:924-6.
  17. EASL International consensus conference on haemochromatosis. J Hepat 2000;33:485-504.
  18. Noll WW, Belloni DR, Stenzel TT, et al. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results [letter; comment]. Nat Genet 1999;23:271-2.
  19. Elsea SH, Leykam V. HFE polymorphism and accurate diagnosis of C282Y hereditary hemochromatosis carriers [letter]. Blood 2000;95:2453-5.
  20. Barton JC, Shih WW, Sawada-Hirai R, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997;23:135-45.
  21. Moirand R, Jouanolle AM, Brissot P, et al. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999;116:372-7.
  22. Brissot P, Moirand R, Jouanolle AM, et al. A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. J Hepatol 1999;30:588-93.
  23. Tay G, Leelayuwat C, Chorney M, et al. The MHC contains multiple genes potentially relevant to hemochromatosis. Immunogenetics 1997;45:336-40.
  24. Whitfield JB, Cullen LM, Jazwinska EC, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000;66:1246-58.
  25. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands. J Med Screen 1996;3:171-7.
  26. Phatak PD, Sham RL, Raubertas RF, et al. Prevalence of hereditary hemochromatosis in 16,031 primary care patients. Ann Intern Med 1998;129:954-61.
  27. McDonnell SM, Hover A, Gloe D, et al. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Amer J Med 1999;107:30-7.
  28. Camaschella C, Fargion S, Sampietro M, et al. Inherited HFE-unrelated hemochromatosis in Italian families. Hepatology 1999;29:1563-4.
  29. Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999;341:725-32.
  30. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-5.
  31. Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999;64:1388-93.
  32. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol 1998;35:55-71.
  33. Adams PC, Deugnier Y, Moirand R, et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
  34. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
  35. Adams PC, Valberg LS. Evolving expression of hereditary hemochromatosis. Semin Liver Dis 1996;16:47-54.
  36. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991;101:368-72.
  37. Moirand R, Adams PC, Bicheler V, et al. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997;127:105-10.
  38. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.
  39. Fargion S, Mandelli C, Piperno A, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-9.
  40. Cogswell ME, McDonnell SM, Khoury MJ, et al. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998;129:971-9.
  41. Witte DL, Crosby WH, Edwards CQ, et al. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
  42. Adams PC. Hemochromatosis: new insights in pathogenesis and diagnosis following the discovery of the gene. Crit Rev Clin Lab Sci 1998;35:239-73.
  43. Edwards CQ, Dadone MM, Skolnick MH, et al. Hereditary haemochromatosis. Clin Haematol 1982;11:411-35.
  44. Finch SC, Finch CA. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine 1955;34:381-430.
  45. Yip R. Iron deficiency. Bull World Health Organ 1998;76:121-3.
  46. Powell LW, Bassett ML. Haemochromatosis: diagnosis and management after the cloning of the HFE gene. Aust N Z J Med 1998;28:159-63.
  47. Niederau C, Niederau CM, Lange S, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998;128:337-45.
  48. Crawford DH, Jazwinska EC, Cullen LM, et al. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998;114:1003-8.
  49. Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998;129:932-9.
  50. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976;45:611-23.
  51. Powell LW, Kerr JF. Reversal of "cirrhosis" in idiopathic haemochromatosis following long- term intensive venesection therapy. Australas Ann Med 1970;19:54-7.
  52. Crosby WH. A history of phlebotomy therapy for hemochromatosis. Am J Med Sci 1991;301:28-31.
  53. Yang Q, McDonnell SM, Khoury MJ, et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 1998;129:946-53.
  54. Burke W, Imperatore G, McDonnell SM, et al. Contribution of different genotypes to iron overload disease: a pooled analysis. Genetics Med (in press).
  55. Levy JE, Montross LK, Andrews NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000;105:1209-16.
  56. Burke W, Press N, McDonnell SM. Hemochromatosis: genetics helps to define a multifactorial disease. Clin Genet 1998;54:1-9.
  57. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-9.
  58. Conte D, Manachino D, Colli A, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998;128:370-3.
  59. Frayling T, Ellard S, Grove J, et al. C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes [letter]. Lancet 1998;351:1933-4.
  60. Dykes A, Volker G, Firkin F. Aetiology of severe iron overload in a family with hereditary haemolytic anemia. Br J Haematol 1998;102:1179-81.
  61. McDonnell SM, Phatak PD, Felitti V, et al. Screening for hemochromatosis in primary care settings. Ann Intern Med 1998;129:962-70.
  62. Adams PC, Gregor JC, Kertesz AE, et al. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology 1995;109:177-88.
  63. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen 1996;3:178-84.
  64. Edwards CQ, Griffen LM, Ajioka RS, et al. Screening for hemochromatosis: phenotype versus genotype. Semin Hematol 1998;35:72-6.
  65. Bell H, Skinningsrud A, Raknerud N, et al. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med 1994;236:315-22.
  66. George DK, Evans RM, Crofton RW, et al. Testing for haemochromatosis in the diabetic clinic. Ann Clin Biochem 1995;32:521-6.
  67. O'Brien T, Barrett B, Murray DM, et al. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care 1990;13:532-4.
  68. McDonnell SM, Witte D. Hereditary hemochromatosis: preventing chronic effects of this underdiagnosed disorder. Postgrad Med 1997;102:83-5, 8-91, 4.
  69. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998;114:319-23.
  70. Bacon BR. Diagnosis and management of hemochromatosis. Gastroenterology 1997;113:995-9.
  71. Willis G, Wimperis JZ, Smith KC, et al. Haemochromatosis gene C282Y homozygotes in an elderly male population [letter]. Lancet 1999;354:221-2.
  72. Resident population estimates of the United States by sex, race and Hispanic Origin: April 1, 1990 to November 1, 1999: U.S. Census Bureau, 1999: http//www.census.gov/population/estimates/nation/intfile3-1.txt.
  73. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998;280:172-8.
  74. Haddow JE, Bradley LA. Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled [editorial]. BMJ 1999;319:531-2.
  75. Sampson MJ, Williams T, Heyburn PJ, et al. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 2000;135:170-3.
  76. Alper JS, Geller LN, Barash CI, et al. Genetic discrimination and screening for hemochromatosis. J Public Health Policy 1994;15:345-8.
  77. Balan V, Baldus W, Fairbanks V, et al. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology 1994;107:453-9.
  78. Phatak PD, Guzman G, Woll JE, et al. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994;154:769-76.
  79. Adams PC. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet 1998;53:176-8.
  80. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000;132:261-9.
  81. Aguilar Martinez P, Biron C, Blanc F, et al. Compound heterozygotes for hemochromatosis gene mutations: may they help to understand the pathophysiology of the disease? Blood Cells Mol Dis 1997;23:269-76.
  82. Borot N, Roth M, Malfroy L, et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics 1997;45:320-4.
  83. Gottschalk R, Seidl C, Loffler T, et al. HFE codon 63/282 (H63D/C282Y) dimorphism in German patients with genetic hemochromatosis. Tissue Antigens 1998;51:270-5.
  84. Ryan E, O'Keane C, Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998;24:428-32.
  85. Piperno A, Sampietro M, Pietrangelo A, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998;114:996-1002.
  86. Miedzybrodzka Z, Loughlin S, Baty D, et al. Haemochromatosis mutations in North-East Scotland. Br J Haematol 1999;106:385-7.
  87. Cardoso EM, Stal P, Hagen K, et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 1998;243:203-8.
  88. Robson KJ, Worwood M, Shearman JD. A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997;41:841-4.
  89. Sham RL, Ou CY, Cappuccio J, et al. Correlation between genotype and phenotype in hereditary hemochromatosis: analysis of 61 cases. Blood Cells Mol Dis 1997;23:314-20.
  90. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996;22:187-94.
  91. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H [letter]. Nat Genet 1996;14:249-51.
  92. Steffensen R, Varming K, Jersild C. Determination of gene frequencies for two common haemochromatosis mutations in the Danish population by a novel polymerase chain reaction with sequence-specific primers. Tissue Antigens 1998;52:230-5.
  93. Merryweather-Clarke AT, Simonsen H, Shearman JD, et al. A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Hum Mutat 1999;13:154-9.
  94. Jezequel P, Bargain M, Lellouche F, et al. Allele frequencies of hereditary hemochromatosis gene mutations in a local population of west Brittany. Hum Genet 1998;102:332-3.
  95. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
  96. Murphy S, Curran MD, McDougall N, et al. High incidence of the Cys282Tyr mutation in the HFE gene in the Irish population- implications for haemochromatosis. Tissue Antigens 1998;52:484-8.
  97. Distante S, Berg JP, Lande K, et al. High Prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 1999;5:529-34.
  98. Sanchez M, Brugera M, Bosch J, et al. Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol 1998;29:725-8.
  99. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998;43:830-6.
  100. de Villiers JN, Hillerman R, de Jong G, et al. High prevalence of the Cys282Tyr HFE mutation facilitates an improved diagnostic service for hereditary haemochromatosis in South Africa. S Afr Med J 1999;89:279-82.
  101. Sohda T, Yanai J, Soejima H, et al. Frequencies in the Japanese population of HFE gene mutations. Biochem Gen 1999;37:63-8.
  102. Marshall DS, Linfert DR, Tsongalis GJ. Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population. Int J Mol Med 1999;4:389-93.
  103. Bradley LA, Johnson DD, Palomaki GE, et al. Hereditary hemochromatosis mutation frequencies in the general population. J Med Screen 1998;5:34-6
Page last reviewed: March 12, 2001 (archived document)
Page last updated: November 2, 2007
Content Source: National Office of Public Health Genomics